Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial

BACKGROUND: Currently, there are no randomized trials on the effect of antiangiogenic therapy in patients with esophageal squamous cell carcinoma (ESCC). The following study investigated the efficacy and safety of anlotinib in patients with advanced ESCC who were previously treated with chemotherapy...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Main Authors: Huang, Jing, Xiao, Juxiang, Fang, Wentao, Lu, Ping, Fan, Qingxia, Shu, Yongqian, Feng, Jifeng, Zhang, Shu, Ba, Yi, Zhao, Yang, Liu, Ying, Bai, Chunmei, Bai, Yuxian, Tang, Yong, Song, Yan, He, Jie
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2021
Assuntos:
Clinical Cancer Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7940231/
https://ncbi.nlm.nih.gov/pubmed/33586360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3771
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares